BlueSphere Bio’s CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector needs to get right in the short term and why.

Ring Therapeutics was launched to take advantage of the viral residents of our bodies – the vast majority of which are anelloviruses. 

The FDA has lifted theclinical hold on Selecta Biosciences’ gene therapy to treat methylmalonic acidemia, a rare disease in children that affects metabolism. The company is now back in the saddle as it preps for a phase 1 trial. 

France-based biologics company Valneva will be advancing toward U.S. Food and Drug Administration accelerated approval of its specialty vaccine, VLA1553. The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.

 To combat the problem of antifungal resistance, Scynexis developed an entirely new class of fungicide: triterpenoid antifungal, which doctors can prescribe when first-line azole treatments don’t work.

Anixa recently launched a Phase I trial of its breast cancer vaccine in patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. 

Her company AltruBio focuses on novel therapeutics for immunological diseases, concentrating on unmet medical needs. The company’s lead candidate, therapeutic antibody neihulizumab, has demonstrated clinical proof of efficacy in treating multiple autoimmune and immune-mediated diseases.  

TFF Pharmaceuticals is on the hunt for new partners, and a recently-announced agreement with Catalent could help them land just that.